Oncology Stream

New Strategies for Targeting Solid Tumors and the Tumor Microenvironment

One of the biggest challenges for cancer therapeutics, is the targeting of solid tumors. Poor tumor tissue penetration and the heterogeneous distribution have limited the clinical efficacy of therapeutic antibodies. Striking advances in bispecific/multispecific antibodies, T cell engagers and antibody-drug conjugates are now leading the way in oncology discovery, with new strategies to target solid tumors and the tumor microenvironment. This year’s PEGS Boston will present the latest and hottest in antibody-based therapies for cancer, highlight the emerging and new-again targets, as well as showcase the exciting resurgence of antibody-drug conjugates as a hot therapeutic modality. Together, the 3 conferences in this stream will present a comprehensive look at strategies driving toward clinical success.

Conferences Include:

May 15-16

Antibodies for Cancer Therapy

May 16-17

Emerging Targets for Oncology and Beyond

May 18-19

Driving Clinical Success in Antibody Drug Conjugates

Keynote Presentations:

Antibody Therapeutics in Early Clinical Development: Format, Target, and Disease Trends
Janice M. ReichertJanice M. Reichert, PhD, Chief Operating Officer, The Antibody Society

Targeting ROR1 with Antibody-Based Cancer Therapy
Christoph RaderChristoph Rader, PhD, Professor, Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida

Trastuzumab Deruxtecan – Successful ADC Development from Payload Selection to Multi-Indication Approval
Gerold MeinhardtGerold Meinhardt, MD, PhD, Vice President – Asset & Portfolio Management, Global Team Lead, DS-8201/ENHERTU, Daiichi Sankyo, Inc.

Mirvetuximab Soravtansine: A Novel FR Alpha-Targeted ADC for Platinum-Resistant Ovarian Cancer
Elisabeth DiverElisabeth Diver, MD, Medical Director, ImmunoGen

Register Now

View By: